Can UCB Make Its Mark In Myasthenia Gravis?

Playing Catch-Up With Alexion And Argenx

 
• By Kevin Grogan
  
Market share
UCB hopes to get a decent slice of the myasthenia gravis market • Source: Shutterstock

More from Rare Diseases

More from Scrip